Ann: Imugene PD1-Vaxx patent extended to 2040, page-109

Yuman presumably has new information to impart in July;
would not come all that way just to repeat what has been told
on his prior visit, and it seems that the possibilities of the
treatment applications maybe expanded, which will be of
extra advantage for commercial uptake. We have the ip,
funding for trials, fda on side, pharma interest and collaboration,
wonderful trial outcomes so far, frequent updates, no
other company is doing better than that to my knowledge
- the long awaited trading halt can be here by eoy imo
The share price is difficult for some, but the real outcome
not doubtful.